Is CTMX Stock Undervalued?

A comprehensive valuation analysis of CytomX Therapeutics Inc (CTMX) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated July 21, 2026•8 min read•View Full Analysis

Valuation Verdict

→

Fairly Valued

0.0% downside risk

Based on our analysis, CytomX Therapeutics Inc appears to be fairly valued at the current price of $0.00. Our fair value estimate of $484043904.19 suggests downside risk of approximately 0.0%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing CTMX relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

N/A

P/B Ratio

N/A

P/S Ratio

N/A

EV/EBITDA

N/A

Understanding the Metrics

P/E Ratio: Not currently profitable or data unavailable.
P/B Ratio: Book value data not available.
P/S Ratio: Revenue data not available.
EV/EBITDA: EBITDA data not available.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of CytomX Therapeutics Inc stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$0.00

Fair Value Estimate

$484043904.19

Implied Return0.0%

CTMX appears fairly valued, trading within 15% of our intrinsic value estimate. The market price closely reflects the fundamental value we calculate.

Investment Conclusion

Bottom Line

CytomX Therapeutics Inc (CTMX) appears fairly valued at $0.00, trading in line with our fundamental analysis. The stock may be appropriate for investors seeking exposure to Healthcare without significant valuation risk.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.